- Home
- Publications
- Publication Search
- Publication Details
Title
Update on disease-modifying therapies for multiple sclerosis
Authors
Keywords
-
Journal
JOURNAL OF INVESTIGATIVE MEDICINE
Volume 65, Issue 5, Pages 883-891
Publisher
BMJ
Online
2017-01-28
DOI
10.1136/jim-2016-000339
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
- (2016) Ralf Gold et al. BMC Neurology
- Defining secondary progressive multiple sclerosis
- (2016) Johannes Lorscheider et al. BRAIN
- Secondary Progressive Multiple Sclerosis: Definition and Measurement
- (2016) Domenico Plantone et al. CNS DRUGS
- Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
- (2016) Roland Martin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The role of global and regional gray matter volume decrease in multiple sclerosis
- (2016) Matthias Grothe et al. JOURNAL OF NEUROLOGY
- Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
- (2016) Irene Cortese et al. NEUROLOGY
- PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
- (2016) Klaus Lehmann-Horn et al. NEUROLOGY
- Fingolimod-associated PML in a patient with prior immunosuppression
- (2016) Tirisham V. Gyang et al. NEUROLOGY
- The use of immune modulating drugs for the treatment of multiple sclerosis
- (2016) Fahd Al-Khamis Neurosciences
- Immunological treatment of multiple sclerosis
- (2016) Martin Diebold et al. SEMINARS IN HEMATOLOGY
- Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence
- (2016) Bhupendra O. Khatri Therapeutic Advances in Neurological Disorders
- Monoclonal Antibodies for Multiple Sclerosis Treatment
- (2015) Filipe Palavra Acta Medica Portuguesa
- The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study
- (2015) Léorah Freeman et al. ANNALS OF NEUROLOGY
- Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
- (2015) Aaron E. Miller CLINICAL THERAPEUTICS
- Gray matter damage in multiple sclerosis: Impact on clinical symptoms
- (2015) Caspar E.P. van Munster et al. NEUROSCIENCE
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
- (2015) Dennis J. Nieuwkamp et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
- (2015) Thorsten Rosenkranz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Disease Modifying Therapies
- (2015) L Garcia Bujalance et al. VALUE IN HEALTH
- An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations
- (2015) Barbara Kornek Patient Preference and Adherence
- Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes
- (2015) Jan Lycke Therapeutic Advances in Neurological Disorders
- Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
- (2015) Roberto Bomprezzi Therapeutic Advances in Neurological Disorders
- B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions
- (2015) Nele Claes et al. Frontiers in Immunology
- Teriflunomide for the Treatment of Relapsing Multiple Sclerosis
- (2014) Luigi Brunetti et al. ANNALS OF PHARMACOTHERAPY
- Natalizumab treatment for multiple sclerosis
- (2014) Maria Lucia Brito Ferreira ARQUIVOS DE NEURO-PSIQUIATRIA
- The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
- (2014) Pawel Kawalec et al. Current Neuropharmacology
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
- (2014) Amit Bar-Or EXPERIMENTAL NEUROLOGY
- Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety
- (2014) David E Jones et al. Expert Review of Clinical Immunology
- Alemtuzumab for the treatment of relapsing–remitting multiple sclerosis
- (2014) Carrie M Hersh et al. Immunotherapy
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- (2014) O. Tuohy et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
- (2014) Gavin Giovannoni et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
- (2014) Dean M. Wingerchuk et al. MAYO CLINIC PROCEEDINGS
- Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
- (2014) Ralf Gold et al. Multiple Sclerosis Journal
- Gender and autoimmune comorbidity in multiple sclerosis
- (2014) Melinda Magyari et al. Multiple Sclerosis Journal
- Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes
- (2014) G. Giovannoni et al. NEUROLOGY
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
- (2014) P. S. Sorensen et al. NEUROLOGY
- Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
- (2014) Jiwon Oh et al. Therapeutic Advances in Neurological Disorders
- Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
- (2014) Vissia Viglietta et al. Annals of Clinical and Translational Neurology
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis
- (2013) Fred D. Lublin et al. ANNALS OF NEUROLOGY
- Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects
- (2013) Ralf A. Linker et al. Current Neurology and Neuroscience Reports
- The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment
- (2013) Silvia Messina et al. Expert Opinion on Drug Metabolism & Toxicology
- Fingolimod for the treatment of relapsing multiple sclerosis
- (2013) Barry A Singer Expert Review of Neurotherapeutics
- The Immune Pathogenesis of Multiple Sclerosis
- (2013) Robert Weissert Journal of Neuroimmune Pharmacology
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis
- (2013) Heinz Wiendl et al. Nature Reviews Neurology
- PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
- (2013) Bob W. van Oosten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis
- (2013) Martin Stangel et al. Expert Review of Clinical Pharmacology
- The cost burden of multiple sclerosis in the United States: a systematic review of the literature
- (2013) Gabriel Adelman et al. JOURNAL OF MEDICAL ECONOMICS
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Progressive multiple sclerosis: pathology and pathogenesis
- (2012) Hans Lassmann et al. Nature Reviews Neurology
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)
- (2012) Niklas Schmedt et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Multiple Sclerosis: Pathogenesis and Treatment
- (2011) Ingrid Loma et al. Current Neuropharmacology
- Teriflunomide shows promise for MS treatment in phase III trial
- (2011) Heather Wood Nature Reviews Neurology
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination
- (2011) Volker Limmroth et al. Therapeutic Advances in Neurological Disorders
- Glatiramer acetate: successful desensitization for treatment of multiple sclerosis
- (2010) Sonia N. Bains et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
- (2010) Joanne L. Jones et al. BRAIN
- Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
- (2010) Corinna Trebst et al. CURRENT MEDICINAL CHEMISTRY
- Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group
- (2010) Sheila A Doggrell EXPERT OPINION ON PHARMACOTHERAPY
- Oral fingolimod for relapsing-remitting multiple sclerosis
- (2010) Sheila A Doggrell EXPERT OPINION ON PHARMACOTHERAPY
- Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis
- (2010) Edward J Fox Expert Review of Neurotherapeutics
- PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis
- (2010) Darren P. Baker et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy
- (2010) Dimitros Karussis et al. JOURNAL OF NEUROIMMUNOLOGY
- Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options
- (2010) Robert A Bermel et al. LANCET NEUROLOGY
- New drugs may improve, complicate treatment for multiple sclerosis
- (2010) NATURE MEDICINE
- Environmental factors and their timing in adult-onset multiple sclerosis
- (2010) Adam E. Handel et al. Nature Reviews Neurology
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a
- (2009) Peter Joseph Jongen et al. JOURNAL OF NEUROLOGY
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis
- (2009) F. Patti et al. Multiple Sclerosis Journal
- The mechanism of action of glatiramer acetate treatment in multiple sclerosis
- (2009) M. K. Racke et al. NEUROLOGY
- Leflunomide-Associated Progressive Multifocal Leukoencephalopathy
- (2008) Megan Rahmlow et al. ARCHIVES OF NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now